- Home
- TSHA vs TCPC Comparison
TSHA vs TCPC Comparison
Compare TSHA & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TCPC
- Stock Information
- Founded
- TSHA 2019
- TCPC 2006
- Country
- TSHA United States
- TCPC United States
- Employees
- TSHA N/A
- TCPC N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- TSHA Health Care
- TCPC Finance
- Exchange
- TSHA Nasdaq
- TCPC Nasdaq
- Market Cap
- TSHA 728.4M
- TCPC 603.8M
- IPO Year
- TSHA 2020
- TCPC 2012
- Fundamental
- Price
- TSHA $3.02
- TCPC $6.93
- Analyst Decision
- TSHA Strong Buy
- TCPC Sell
- Analyst Count
- TSHA 7
- TCPC 2
- Target Price
- TSHA $8.71
- TCPC $6.75
- AVG Volume (30 Days)
- TSHA 3.5M
- TCPC 434.5K
- Earning Date
- TSHA 11-12-2025
- TCPC 11-05-2025
- Dividend Yield
- TSHA N/A
- TCPC 17.55%
- EPS Growth
- TSHA N/A
- TCPC N/A
- EPS
- TSHA N/A
- TCPC N/A
- Revenue
- TSHA $8,098,000.00
- TCPC $239,535,768.00
- Revenue This Year
- TSHA N/A
- TCPC N/A
- Revenue Next Year
- TSHA N/A
- TCPC N/A
- P/E Ratio
- TSHA N/A
- TCPC N/A
- Revenue Growth
- TSHA N/A
- TCPC 3.11
- 52 Week Low
- TSHA $1.05
- TCPC $6.27
- 52 Week High
- TSHA $3.40
- TCPC $9.72
- Technical
- Relative Strength Index (RSI)
- TSHA 51.14
- TCPC 38.34
- Support Level
- TSHA $3.16
- TCPC $7.09
- Resistance Level
- TSHA $2.99
- TCPC $7.28
- Average True Range (ATR)
- TSHA 0.18
- TCPC 0.12
- MACD
- TSHA -0.01
- TCPC -0.00
- Stochastic Oscillator
- TSHA 38.21
- TCPC 2.78
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.